ER + breast tumors often establish an immunosuppressive tumor microenvironment (TME) with low levels of tumor-infiltrating lymphocytes (TILs) and PD-L1, making them resistant to PD-1 therapies [36, 37]. The gene discussed is CD274; the disease is breast neoplasm.